Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Raised by Tidal Investments LLC

Tidal Investments LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 36.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,346 shares of the medical research company's stock after acquiring an additional 21,643 shares during the quarter. Tidal Investments LLC's holdings in Thermo Fisher Scientific were worth $41,798,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Stonegate Investment Group LLC increased its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after buying an additional 18 shares during the last quarter. Semus Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.0% in the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after purchasing an additional 18 shares during the period. KRS Capital Management LLC increased its position in Thermo Fisher Scientific by 1.5% during the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock worth $685,000 after purchasing an additional 20 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares in the last quarter. Finally, Evernest Financial Advisors LLC increased its position in shares of Thermo Fisher Scientific by 4.0% in the fourth quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock worth $271,000 after acquiring an additional 20 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Raymond James reissued an "outperform" rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded down $0.45 during mid-day trading on Tuesday, hitting $413.47. The stock had a trading volume of 2,141,884 shares, compared to its average volume of 1,845,527. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a market cap of $156.08 billion, a PE ratio of 25.01, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The company's fifty day simple moving average is $449.99 and its two-hundred day simple moving average is $508.22.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the firm earned $5.11 earnings per share. The firm's revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.